Antiproliferative activity of semisynthetic xylopic acid derivatives

Our plain-English summary of Antiproliferative activity of semisynthetic xylopic acid derivatives, by D. Soh, N. Ernestine, E.M. Tchana Satchet, et al (Natural Product Research, 2022).

The study

• Authors: D. Soh, N. Ernestine, E.M. Tchana Satchet, U.D. Defokou, B. Schneider, V. Giovanni, B. Nyassé
• Journal: Natural Product Research
• Published: 2022;36(5):1288-1295
• Cited by: 5 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

Two ent-kaurene diterpenoids, ent-15-β-acetyloxy-kaur-16-en-19-oic acid (xylopic acid) 1 and ent-7-oxo-kaur-16-en-19-oic acid 2 were isolated from the fruits of Xylopia aethiopica. Chemical manipulation of xylopic acid yielded ent-kaurane derivatives 3, 4, 5, and 6. Their structures were elucidated by spectroscopic analysis, including 1 D- and 2 D-NMR spectroscopies. The antiproliferative activities of compounds 1, 2, 3, 4, and 6 were tested on breast MCF7 and SkBr3, endometrial Ishikawa, ovarian BG-1, mesothelioma IST-MES1 and hepatocellular HepG2 human tumor cells, and on mammalian MRC-10 fibroblast cells. Ketone 2 showed significant antiproliferative activity against MFC7 human breast cancer cells (IC50 = 3 ± 1 µM) and A549 pulmonary adenocarcinoma (8 ± 1 µM), that was higher than the well-known anti-cancer agent cisplatin (IC50 = 19 ± 3 and 15 ± 4 µM, respectively).[Formula: see text].

In plain English

This was a laboratory chemistry and cell-culture study. It did not study people or asbestos exposure. The authors isolated two plant compounds from the fruits of the African tree Xylopia aethiopica: xylopic acid (compound 1) and a related compound (compound 2). They then chemically converted xylopic acid into further compounds (3 to 6). They tested compounds 1, 2, 3, 4 and 6 against human tumor cells grown in the laboratory and compared them with the cancer drug cisplatin. The cells included a mesothelioma cell line called IST-MES1, as well as breast, endometrial, ovarian and lung adenocarcinoma lines. A noncancerous fibroblast line was also tested. For the mesothelioma cells, the concentration of compound 2 that left half the cells alive (IC50) was 7 ± 2 micromolar, against 8 ± 1 for cisplatin. In MCF7 breast cancer cells the figures were 3 ± 1 for compound 2 and 19 ± 3 for cisplatin. Compound 4 was inactive. Compound 3 was moderately active against MCF7 and A549 cells only. The authors concluded that activity depended on the chemical groups at particular positions of the molecule.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory study: isolation of plant compounds, chemical synthesis of derivatives, and an in vitro cell growth (MTT) assay
• Who was studied: Human cancer cell lines: MCF7 and SkBr3 breast, Ishikawa endometrial, BG-1 ovarian, IST-MES1 mesothelioma and A549 lung adenocarcinoma, plus the noncancerous MRC-10 fibroblast line. No human participants.
• Exposure: No asbestos exposure. Cells were exposed to xylopic acid and related compounds from Xylopia aethiopica fruits, and to the reference drug cisplatin, at concentrations from 0.1 to 150, for two days.
• Main results:
  • Compound 2 IC50 values (micromolar) were 3 ± 1 in MCF7, 9 ± 2 in SkBr3, 7 ± 2 in IST-MES1 mesothelioma, 8 ± 1 in A549, 7 ± 2 in BG-1 and 7 ± 2 in Ishikawa cells.
  • Cisplatin IC50 values (micromolar) were 19 ± 3 in MCF7, 4 ± 3 in SkBr3, 8 ± 1 in IST-MES1 mesothelioma, 15 ± 4 in A549, 7 ± 3 in BG-1 and 13 ± 2 in Ishikawa cells.
  • The authors reported that compound 2 was more active than cisplatin against all tumor cell lines except SkBr3.
  • Compound 4 was inactive. Compound 3 was moderately active against MCF7 and A549 cells; its IC50 was above 50 in the mesothelioma and other lines.
• The authors' conclusion: The authors concluded that the activity of the xylopic acid derivatives depends on the chemical groups at positions C-7, C-15 and C-16. They believe this could help in designing related compounds with higher activity against cells.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma, Fibroblast, Adenocarcinoma, Cisplatin.

Related studies

• Exploring structural and biological insights of TEAD through rational design and synthesis of niflumic acid derivatives — Y.S. Choi, Y.J. Kim, et al. (2024)
• Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells — M. Alessio, I. Zanellato, et al. (2013)
• Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells — S. Amatori, F. Papalini, et al. (2009)
• The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells — A. Pattarozzi, E. Carra, et al. (2017)
• Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells — Y. Takemura, M. Satoh, et al. (2018)
• Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors — P. Tiberio, E. Cavadini, et al. (2017)

Browse return to medical research.